AJP - Heart Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 289: H708-H714, 2005. First published April 8, 2005; doi:10.1152/ajpheart.01179.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/H708    most recent
01179.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woldbæk, P. R.
Right arrow Articles by Tønnessen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woldbæk, P. R.
Right arrow Articles by Tønnessen, T.

Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice

Per Reidar Woldbæk,1,2 Jørn Bodvar Sande,1 Tævje Andreas Strømme,1 Per Kristian Lunde,1 Srdjan Djurovic,4 Torstein Lyberg,3 Geir Christensen,1 and Theis Tønnessen1,2

1Institute for Experimental Medical Research, 2Department of Cardiothoracic Surgery, 3Center for Clinical Research, and 4Institute for Medical Genetics, Ullevål University Hospital, University of Oslo, Oslo, Norway

Submitted 23 November 2004 ; accepted in final form 6 April 2005

Although increased levels of circulating interleukin (IL)-18 have been demonstrated in patients with cardiovascular diseases, the functional consequences of chronically increased circulating IL-18 with respect to myocardial function have not been defined. Thus we aimed to examine the effects of chronic IL-18 exposure on left ventricular (LV) function in healthy mice. Moreover, to clarify whether IL-18 has direct effects on the cardiomyocyte, we examined effects of IL-18 on cardiomyocytes in vitro. After 7 days of daily intraperitoneal injections of 0.5 µg IL-18 in healthy mice, a 40% (P < 0.05) reduction in the LV maximal positive derivative, a 25% (P < 0.05) reduction in the LV maximal rate of pressure decay, and a 2.8-fold (P < 0.001) increase in the LV end-diastolic pressure were measured, consistent with myocardial dysfunction. Furthermore, we measured a 75% (P < 0.05) reduction in {beta}-adrenergic responsiveness to isoproterenol. IL-18 induced myocardial hypertrophy, and there was a 2.9-fold increase (P < 0.05) in atrial natriuretic peptide mRNA expression in the LV myocardium. In vitro examinations of isolated adult rat cardiomyocytes being stimulated with IL-18 (0.1 µg/ml) exhibited an increase in peak Ca2+ transients (P < 0.05) and in diastolic Ca2+ concentrations (P < 0.05). In conclusion, this study shows that daily administration of IL-18 in healthy mice causes LV myocardial dysfunction and blunted {beta}-adrenergic responsiveness to isoproterenol. A direct effect of IL-18 on the cardiomyocyte in vitro was demonstrated, suggesting that IL-18 reduces the responsiveness of the myofilaments to Ca2+. Finally, induction of myocardial hypertrophy by IL-18 indicates a role for this cytokine in myocardial remodeling.

cytokines; heart failure; contractile function; calcium



Address for reprint requests and other correspondence: P. R. Woldbæk, Institute for Experimental Medical Research, Ullevål University Hospital, 0407 Oslo, Norway (e-mail: pewo{at}uus.no)




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson
IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H76 - H85.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K.-O. Larsen, B. Lygren, I. Sjaastad, K. A. Krobert, K. Arnkvaern, G. Florholmen, A.-K. R. Larsen, F. O. Levy, K. Tasken, O. H. Skjonsberg, et al.
Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A
Cardiovasc Res, October 1, 2008; 80(1): 47 - 54.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Doi, T. Sakoda, T. Akagami, T. Naka, Y. Mori, T. Tsujino, T. Masuyama, and M. Ohyanagi
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1279 - H1287.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
A Platis, Q Yu, D Moore, E. Khojeini, P Tsau, and D. Larson
The effect of daily administration of IL-18 on cardiac structure and function
Perfusion, July 1, 2008; 23(4): 237 - 242.
[Abstract] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al.
Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13
Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 49 - 62.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella
IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway
J. Immunol., July 1, 2006; 177(1): 234 - 245.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.